2mg vial
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. Across decades of research it has been studied for slow-wave sleep promotion, circadian regulation, stress-axis modulation and analgesic effects, with a notably benign tolerability profile.
Checking availability…
Exact receptor target remains uncharacterised. Demonstrated effects include modulation of the HPA axis (reduced ACTH/cortisol output), normalisation of delta-wave EEG architecture, and interaction with opioidergic and GABAergic systems.
Common research protocols use 100–300mcg subcutaneously 30–60 minutes before bed, or intranasally. Cycles typically run 4–8 weeks with intermittent use rather than daily long-term administration.
Plasma half-life is short (approx. 7–20 minutes), but downstream effects on sleep architecture persist well beyond clearance.
Reconstitute a 5mg vial with 2–5mL bacteriostatic water for a 1–2.5mg/mL working concentration. Swirl gently.
Lyophilised: 2–8°C, stable 18–24 months; -20°C for long-term storage. Reconstituted: 2–8°C, protect from light, use within 30 days.